Impact BioMedical, INC. Entity Listing, Par Value Per Share
Impact BioMedical, INC. (IBO) reported Entity Listing, Par Value Per Share of $0.00 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Cover Page
dei:EntityListingParValuePerShare · last filed 2026-08-07
- Impact BioMedical, INC. entity listing, par value per share for the quarter ending 2026-03-31 was $0.00, a 0.00% change year-over-year.
- Impact BioMedical, INC. entity listing, par value per share for the quarter ending 2025-03-31 was $0.00.
- Impact BioMedical, INC. entity listing, par value per share for fiscal 2025 was $0.00, a 0.00% change from fiscal 2024.
- Impact BioMedical, INC. entity listing, par value per share for fiscal 2024 was $0.00.
| Period end | Entity Listing, Par Value Per Share 3 month | Entity Listing, Par Value Per Share 6 month | Entity Listing, Par Value Per Share 9 month | Entity Listing, Par Value Per Share 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-07 | |||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $0.00 10-K · filed 2026-03-11 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-07 | |||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | $0.00 10-K · filed 2025-03-28 | |||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |